Developer docs
API playgroundTry for free, no card

Search company profiles

venBio Partners

Full company profile

uuid0003fre

Namestring
venBio Partners
Legal namestring
venBio Partners LLC
Websiteurl
venbio.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

venBio Partners is a San Francisco-based life sciences venture capital firm founded in 2011 that invests exclusively in clinical-stage biotechnology companies developing novel therapeutics for unmet medical needs. The firm operates with a small team (1-10 employees) across offices in San Francisco and Seattle, and applies a proprietary "Four D's" investment thesis focused on real drugs, real differentiation, real data, and real diseases. Portfolio companies span multiple therapeutic modalities and stages, including radioligand therapies (Abdera Therapeutics), immunology bispecifics (Caldera Therapeutics), inflammatory/autoimmune biologics (Attovia Therapeutics), FcRn antagonists (Parabilis Medicines), vaccines (Vicebio, acquired by Sanofi in July 2025 for US$1.6B), and clinical-stage assets across IBD, hereditary angioedema, and smoking cessation.

The firm has raised five institutional venture funds, with cumulative committed capital of approximately $1.1 billion per the company website (fourth fund of $550M in 2021 and fifth fund of $528M in 2024). venBio's revenue model follows standard VC economics: recurring management fees on committed/invested capital plus carried interest on realized exits. Limited Partners include strategic partners (large biotech and pharma companies) and qualified financial investors (e.g., RA Capital, Fidelity, Janus Henderson, Wellington, Omega Funds, ARCH, GV, General Catalyst). The firm's go-to-market is relationship-driven, leveraging LP diligence participation, expert advisor networks, and syndication with leading healthcare investors to source and validate deals. Notable outcomes include one FDA-approved drug from the portfolio and the 2025 Sanofi acquisition of Vicebio, validating the firm's positioning approach of building companies toward strategic acquisition from inception.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funding, life sciences investing, biotech venture capital, therapeutics investment, pharmaceutical VC funds
Industry1 code
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
NAICS code2 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Finance Services6199
Product category
Life Sciences Venture Capital
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

venBio Partners is a life sciences venture capital firm founded in 2011 and headquartered in San Francisco that invests in biotechnology companies developing novel therapeutics. The firm manages venture capital funds with committed capital of nearly $1.1 billion (per firm website) — or close to $2 billion including the fifth fund of $528 million — and partners with entrepreneurs to build innovative therapeutic companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

venBio Partners is a life sciences venture capital investment firm that does not offer products or services in the traditional sense. The firm manages venture funds investing in biotechnology and life sciences companies developing novel therapeutics for unmet medical needs. As an investment firm, their offering consists of venture capital funding, portfolio company support, and investment management services for their limited partners.

Product and service1 record
1venBio Partners Venture Capital Funds (Fund I–V)
CategoryLife Sciences Venture Capital
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or Integration
Description

Licensed Molecular Clamp technology from University of Queensland to Vicebio. Technology transfer and licensing partnership for vaccine development.

Strategic tierCoreTypeTechnology or Integration
Description

Licensed exclusive global development and commercialization rights to CLD-423 to Caldera Therapeutics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

5AM Ventures is an early-stage life sciences venture firm investing in biotech and platform technologies. It is directly comparable to venBio in stage, sector focus, and check size discipline.

TypeEmerging player
Description

Third Rock Ventures is a biotech venture creator that conceives, builds, and launches new therapeutic companies. While structurally different, it is comparable to venBio in its life sciences focus, operating involvement, and mission of building category-defining biotechs.

TypeBroad incumbent
Description

NEA is a large, multi-stage venture firm with a significant healthcare/biotech practice alongside technology investments. It is broader than venBio but competes for similar biotech deals and represents a larger, more diversified incumbent.

TypeDirect peer
Description

Atlas Venture is a leading early-stage life sciences venture capital firm that builds and invests in biotech companies. It co-invested with venBio in Caldera Therapeutics and shares a comparable stage focus, sector specialization, and syndicate network.

TypeDirect peer
Description

OrbiMed is one of the largest dedicated healthcare investment firms globally, investing across private and public biotech, medtech, and healthcare services. It is a natural peer given its pure-play life sciences focus, scale, and late-stage participation.

TypeDirect peer
Description

Frazier Life Sciences is a dedicated healthcare and life sciences venture firm investing across public and private biotech. It has co-led multiple rounds with venBio (e.g., Attovia, Achieve Life Sciences) and operates with a similar biotech-only mandate and stage focus.

TypeDirect peer
Description

RA Capital is a crossover-focused healthcare investment manager with significant biotech private and public investing. It co-led Parabilis' $305M Series F alongside venBio's syndicate, making it a closely comparable late-stage biotech investor.

TypeDirect peer
Description

Versant Ventures is a dedicated healthcare venture firm investing in biotech, medtech, and digital health across stages. It co-led Abdera Therapeutics alongside venBio and shares a comparable biotech-focused, multi-stage investment model.

TypeDirect peer
Description

ARCH Venture Partners is a long-established life sciences and technology venture firm with deep biotech expertise. It participated in Parabilis' Series F alongside venBio and is a directly comparable institutional life sciences investor.

TypeDirect peer
Description

Medicxi is a healthcare-focused venture firm that originated Vicebio and co-invested in subsequent rounds. Its stage focus, sector specialization, and syndicate relationship with venBio make it a closely comparable European-anchored life sciences peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment104 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

venBio Partners

Life Sciences Venture Capitalvenbio.com

What venBio Partners does

venBio Partners is a San Francisco-based life sciences venture capital firm founded in 2011 that invests exclusively in clinical-stage biotechnology companies developing novel therapeutics for unmet medical needs. The firm operates with a small team (1-10 employees) across offices in San Francisco and Seattle, and applies a proprietary "Four D's" investment thesis focused on real drugs, real differentiation, real data, and real diseases. Portfolio companies span multiple therapeutic modalities and stages, including radioligand therapies (Abdera Therapeutics), immunology bispecifics (Caldera Therapeutics), inflammatory/autoimmune biologics (Attovia Therapeutics), FcRn antagonists (Parabilis Medicines), vaccines (Vicebio, acquired by Sanofi in July 2025 for US$1.6B), and clinical-stage assets across IBD, hereditary angioedema, and smoking cessation.

The firm has raised five institutional venture funds, with cumulative committed capital of approximately $1.1 billion per the company website (fourth fund of $550M in 2021 and fifth fund of $528M in 2024). venBio's revenue model follows standard VC economics: recurring management fees on committed/invested capital plus carried interest on realized exits. Limited Partners include strategic partners (large biotech and pharma companies) and qualified financial investors (e.g., RA Capital, Fidelity, Janus Henderson, Wellington, Omega Funds, ARCH, GV, General Catalyst). The firm's go-to-market is relationship-driven, leveraging LP diligence participation, expert advisor networks, and syndication with leading healthcare investors to source and validate deals. Notable outcomes include one FDA-approved drug from the portfolio and the 2025 Sanofi acquisition of Vicebio, validating the firm's positioning approach of building companies toward strategic acquisition from inception.

venBio Partners firmographics

Firmographics
Name
venBio Partners
Legal name
venBio Partners LLC
Website
https://venbio.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

venBio Partners industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Portfolio Management and Investment Advice (523940)
SIC
Finance Services (6199)
akta.pro industry
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms

Keywords

  • Venture capital funding
  • Life sciences investing
  • Biotech venture capital
  • Therapeutics investment
  • Pharmaceutical VC funds

Where venBio Partners is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

venBio Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Distribution channels1 record

Marketing channels4 records

venBio Partners product offering

Product offering

Core offering

venBio Partners is a life sciences venture capital firm founded in 2011 and headquartered in San Francisco that invests in biotechnology companies developing novel therapeutics. The firm manages venture capital funds with committed capital of nearly $1.1 billion (per firm website) — or close to $2 billion including the fifth fund of $528 million — and partners with entrepreneurs to build innovative therapeutic companies.

Product overview

venBio Partners is a life sciences venture capital investment firm that does not offer products or services in the traditional sense. The firm manages venture funds investing in biotechnology and life sciences companies developing novel therapeutics for unmet medical needs. As an investment firm, their offering consists of venture capital funding, portfolio company support, and investment management services for their limited partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • venBio Partners Venture Capital Funds (Fund I–V)

Companies that use venBio Partners

Customer profile

Segments2 records

Ideal customer profiles2 records

venBio Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

venBio Partners partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • UniQuestcoreTechnology or IntegrationLicensed Molecular Clamp technology from University of Queensland to Vicebio. Technology transfer and licensing partnership for vaccine development.
  • Qyuns TherapeuticscoreTechnology or IntegrationLicensed exclusive global development and commercialization rights to CLD-423 to Caldera Therapeutics.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

venBio Partners competitors and assessment

Company assessment

Direct peers

  • 5AM Ventures: 5AM Ventures is an early-stage life sciences venture firm investing in biotech and platform technologies. It is directly comparable to venBio in stage, sector focus, and check size discipline.
  • Atlas Venture: Atlas Venture is a leading early-stage life sciences venture capital firm that builds and invests in biotech companies. It co-invested with venBio in Caldera Therapeutics and shares a comparable stage focus, sector specialization, and syndicate network.
  • OrbiMed: OrbiMed is one of the largest dedicated healthcare investment firms globally, investing across private and public biotech, medtech, and healthcare services. It is a natural peer given its pure-play life sciences focus, scale, and late-stage participation.
  • Frazier Life Sciences: Frazier Life Sciences is a dedicated healthcare and life sciences venture firm investing across public and private biotech. It has co-led multiple rounds with venBio (e.g., Attovia, Achieve Life Sciences) and operates with a similar biotech-only mandate and stage focus.
  • RA Capital Management: RA Capital is a crossover-focused healthcare investment manager with significant biotech private and public investing. It co-led Parabilis' $305M Series F alongside venBio's syndicate, making it a closely comparable late-stage biotech investor.
  • Versant Ventures: Versant Ventures is a dedicated healthcare venture firm investing in biotech, medtech, and digital health across stages. It co-led Abdera Therapeutics alongside venBio and shares a comparable biotech-focused, multi-stage investment model.
  • ARCH Venture Partners: ARCH Venture Partners is a long-established life sciences and technology venture firm with deep biotech expertise. It participated in Parabilis' Series F alongside venBio and is a directly comparable institutional life sciences investor.
  • Medicxi: Medicxi is a healthcare-focused venture firm that originated Vicebio and co-invested in subsequent rounds. Its stage focus, sector specialization, and syndicate relationship with venBio make it a closely comparable European-anchored life sciences peer.

Emerging players

  • Third Rock Ventures: Third Rock Ventures is a biotech venture creator that conceives, builds, and launches new therapeutic companies. While structurally different, it is comparable to venBio in its life sciences focus, operating involvement, and mission of building category-defining biotechs.

Broad incumbents

  • New Enterprise Associates (NEA): NEA is a large, multi-stage venture firm with a significant healthcare/biotech practice alongside technology investments. It is broader than venBio but competes for similar biotech deals and represents a larger, more diversified incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

venBio Partners social profiles

Digital presence

venBio Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

venBio Partners leadership team

Management profile

Number of profiles

Profiles4 records

venBio Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

venBio Partners M&A and investment

M&A and investment

M&A

Investments104 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about venBio Partners

What does venBio Partners do?

venBio Partners is a life sciences venture capital firm founded in 2011 and headquartered in San Francisco that invests in biotechnology companies developing novel therapeutics. The firm manages venture capital funds with committed capital of nearly $1.1 billion (per firm website) — or close to $2 billion including the fifth fund of $528 million — and partners with entrepreneurs to build innovative therapeutic companies.

Is venBio Partners a public or private company?

venBio Partners is a private company. It is classified as management employee owned and is currently operating.

When was venBio Partners founded?

venBio Partners was founded in 2011. It employs 1 to 10 people.

Where is venBio Partners based?

venBio Partners is headquartered in San Francisco, United States, in the North America region.

Who are venBio Partners's main competitors?

Direct peers on record are 5AM Ventures, Atlas Venture, OrbiMed, Frazier Life Sciences, RA Capital Management, Versant Ventures, ARCH Venture Partners and Medicxi. Third Rock Ventures is listed as an emerging player. New Enterprise Associates (NEA) is listed as a broad incumbent.

Does venBio Partners have an API?

No public API is recorded for venBio Partners.

What industry is venBio Partners in?

venBio Partners's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms. Its NAICS code is 525 and its SIC code is 6199.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
STATWith $173 million, new startup takes aim at sickle cellMarrow Therapeutics was founded by Romesh Subramanian with $173 million in Series A and B funding from Scion Life Sciences, venBio, OrbiMed, and others. The startup aims to develop a treatment for sickle cell disease that is as effective as gene therapy but without its drawbacks. Subramanian said the company expects it to be as good as gene therapy in patients.MoomooBravera Bio Secures $171 Million in Series A Funding to Focus on Novel Oncology DrugsBravera Bio closed a $171.09 million Series A round co-led by venBio and others, with BeiGene's subsidiary investing $19.5 million. The deal gives BeiGene about 9.477% equity, and the company will receive funds in three tranches contingent on milestones.MarketBeatvenBio Partners LLC Takes $144.15 Million Position in Parabilis Medicines, Inc. $PBLSvenBio Partners LLC acquired a new stake in Parabilis Medicines, purchasing 5,266,697 shares valued at approximately $144.15 million in Q2. The firm now holds about 4.46% of the company, making it its second-largest holding. Analysts rate the stock a Buy with a consensus target of $41.67.BioSpaceYarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business UpdateYarrow Bioscience reported Q2 2026 results with a $6.5M net loss and $18.7M cash, and initiated its Phase 2a/2b trial of YB-101 for Graves' disease. The company expects Phase 2a topline data in the second half of 2027 and plans to fund operations into 2028.BioSpaceSynlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private PlacementSynlogic and Caldera Therapeutics announced a merger agreement to combine in an all-stock transaction, with the combined company operating as Caldera Therapeutics. Caldera secured a concurrent private placement of approximately $278 million to fund Phase 2 clinical trials, with cash runway projected into 2029. The deal is expected to close by early 2027.FinSMEsOak Hill Bio Raises $32.5M in Series A FundingOak Hill Bio raised $32.5M in Series A financing co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors. The funds will advance rugonersen, an ASO therapy for Angelman syndrome, into a pivotal Phase 3 study. The company also appointed three new board members.BioSpaceOak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman SyndromeOak Hill Bio closed a $32.5 million Series A financing co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors. The funds will advance rugonersen, an antisense oligonucleotide for Angelman syndrome, into a Phase 3 study in mid-2026. The company also added three board members.BioSpaceAchieve Life Sciences Announces Up to $354 Million Private PlacementAchieve Life Sciences announced a private placement for up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable within 20 days of FDA approval. The deal, led by Frazier Life Sciences and others, will fund a Phase 3 trial for cytisinicline in e-cigarette cessation. The placement is expected to close on April 17, 2026.BioPharma DiveLexeo to help launch spinout around RNA drugs for the heartLexeo Therapeutics is spinning out a new biotech company focused on RNA-based medicines for genetically mediated cardiac conditions, with Perceptive Xontogeny Venture Funds and venBio Partners contributing up to $40 million in funding. Lexeo will retain double-digit equity in the new entity and may receive future milestone payments and royalties based on its preclinical science and non-viral delivery technology. This move follows recent workforce reductions and an IPO struggle for Lexeo as it seeks to realize value from its portfolio.Pulse 2.0venBio Reveals $528 Million Global Strategic Fund VvenBio closed its fifth life sciences venture capital fund, Fund V, at about $528 million in capital commitments, exceeding its target. The oversubscribed fund targets biopharmaceutical companies developing drugs for unmet medical needs, with a focus on those showing meaningful clinical data within 3-5 years.